https://novapharmanews.com/eu/news/chmp-may-2026-output-shift-european-drug-development 2026-05-30T13:29:47.339Z NovaPharmaNews en-GB 2026-05-30T13:14:56.236Z CHMP May 2026 Output: A New Era in Drug Approvals https://novapharmanews.com/uploads/articles/chmp-may-2026-drug-approvals.webp CHMP May 2026 Output: A New Era in Drug Approvals https://novapharmanews.com/us/news/lunai-bioworks-brainstorm-therapeutics-ai-collaboration 2026-05-30T16:55:14.829Z NovaPharmaNews en-US 2026-05-30T13:14:56.236Z Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy Parkinson's disease, Rare Epilepsy https://novapharmanews.com/uploads/articles/lunai-bioworks-brainstorm-therapeutics-ai-collaboration.webp Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy https://novapharmanews.com/us/news/states-confront-medical-chatbots-oversight-fda-inaction 2026-05-30T17:31:29.414Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z States Confront Medical Chatbots Oversight Amid FDA Inaction https://novapharmanews.com/uploads/articles/states-confront-medical-chatbots-oversight-fda-inaction.webp States Confront Medical Chatbots Oversight Amid FDA Inaction https://novapharmanews.com/us/news/fda-commissioner-resignation-drug-approvals 2026-05-30T16:27:23.821Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z FDA Commissioner Resignation and Its Impact on Drug Approvals https://novapharmanews.com/uploads/articles/fda-commissioner-resignation-drug-approvals.webp FDA Commissioner Resignation and Its Impact on Drug Approvals https://novapharmanews.com/us/news/life-sciences-dealmaking-momentum-strategic-pressures 2026-05-30T16:26:43.378Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Life Sciences Dealmaking Gains Momentum Amid Strategic Pressures https://novapharmanews.com/uploads/articles/life-sciences-dealmaking-momentum-strategic-pressures.webp Life Sciences Dealmaking Gains Momentum Amid Strategic Pressures https://novapharmanews.com/us/news/big-pharma-biotech-assets-patent-cliff 2026-05-30T16:27:25.815Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Big Pharma's Race for Biotech Assets Amid $170 Billion Patent Cliff https://novapharmanews.com/uploads/articles/big-pharma-biotech-assets-patent-cliff.webp Big Pharma's Race for Biotech Assets Amid $170 Billion Patent Cliff https://novapharmanews.com/us/news/vir-biotechnology-stock-board-reshuffle-governance-votes 2026-05-30T16:28:42.635Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/uploads/articles/vir-biotechnology-stock-board-reshuffle-governance-votes.webp Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/us/news/regulatory-actions-may-2026 2026-05-30T16:27:34.707Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Regulatory Actions in May 2026: Key Updates for Pharma https://novapharmanews.com/uploads/articles/regulatory-actions-may-2026.webp Regulatory Actions in May 2026: Key Updates for Pharma https://novapharmanews.com/us/news/pharma-ma-boom-2026-market-analysis 2026-05-30T16:27:23.252Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Pharma M&A Set to Boom in 2026: Market Analysis https://novapharmanews.com/uploads/articles/pharma-ma-boom-2026-market-analysis.webp Pharma M&A Set to Boom in 2026: Market Analysis https://novapharmanews.com/us/news/big-pharma-ma-spree-march-ipo-drought 2026-05-30T16:27:31.507Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Big Pharma's M&A Spree and the March IPO Drought: An Analysis https://novapharmanews.com/uploads/articles/big-pharma-ma-spree-march-ipo-drought.webp Big Pharma's M&A Spree and the March IPO Drought: An Analysis https://novapharmanews.com/us/news/pharmtech-regulatory-roundup-may-2026-drug-approvals 2026-05-30T16:27:54.374Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z PharmTech’s Regulatory Roundup for May 2026: Drug Approvals https://novapharmanews.com/uploads/articles/pharmtech-regulatory-roundup-may-2026-drug-approvals.webp PharmTech’s Regulatory Roundup for May 2026: Drug Approvals https://novapharmanews.com/us/news/bizengri-fda-national-priority-rare-bile-duct-cancer 2026-05-30T16:27:21.300Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Bizengri Receives FDA National Priority Nod for Rare Bile Duct Cancer Bizengri, rare bile duct cancer https://novapharmanews.com/uploads/articles/bizengri-fda-national-priority-rare-bile-duct-cancer.webp Bizengri Receives FDA National Priority Nod for Rare Bile Duct Cancer https://novapharmanews.com/us/news/regeneron-fda-approval-neurosensory-gene-therapy 2026-05-30T13:28:02.568Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Regeneron Secures FDA Approval for Pioneering Neurosensory Gene Therapy gene therapy https://novapharmanews.com/uploads/articles/regeneron-fda-approval-neurosensory-gene-therapy.webp Regeneron Secures FDA Approval for Pioneering Neurosensory Gene Therapy https://novapharmanews.com/us/news/editas-medicine-inc-stock-quiet-trading-clinical-trials 2026-05-30T16:28:38.495Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Editas Medicine Inc Stock: Quiet Trading Ahead of Clinical Trials https://novapharmanews.com/uploads/articles/editas-medicine-inc-stock-quiet-trading-clinical-trials.webp Editas Medicine Inc Stock: Quiet Trading Ahead of Clinical Trials https://novapharmanews.com/us/news/longeveron-stockholder-letter-corporate-strategy-2026-goals 2026-05-30T16:28:22.037Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Longeveron Stockholder Letter Highlights Corporate Strategy and 2026 Goals https://novapharmanews.com/uploads/articles/longeveron-stockholder-letter-corporate-strategy-2026-goals.webp Longeveron Stockholder Letter Highlights Corporate Strategy and 2026 Goals https://novapharmanews.com/us/news/ai-breast-cancer-risk-prediction-tool-fda-approval 2026-05-30T16:27:15.919Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z AI Breast Cancer Risk Prediction Tool Gains FDA Approval oncology, breast cancer https://novapharmanews.com/uploads/articles/ai-breast-cancer-risk-prediction-tool-fda-approval.webp AI Breast Cancer Risk Prediction Tool Gains FDA Approval https://novapharmanews.com/us/news/ai-brain-organoids-parkinsons-rare-epilepsy-regulatory-updates 2026-05-30T16:26:52.303Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z AI and Brain Organoids Combat Parkinson's and Rare Epilepsy Parkinson's disease, Rare Epilepsy https://novapharmanews.com/uploads/articles/ai-brain-organoids-parkinsons-rare-epilepsy-regulatory-updates.webp AI and Brain Organoids Combat Parkinson's and Rare Epilepsy https://novapharmanews.com/us/news/pfizer-innovent-deal-global-drug-development-oncology 2026-05-30T16:26:36.281Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Pfizer-Innovent Deal: A New Model for Global Drug Development in Oncology oncology https://novapharmanews.com/uploads/articles/pfizer-innovent-deal-global-drug-development-oncology.webp Pfizer-Innovent Deal: A New Model for Global Drug Development in Oncology https://novapharmanews.com/eu/news/pfizer-innovent-cancer-drug-alliance 2026-05-30T16:27:44.204Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Form $10.5 Billion Cancer Drug Alliance oncology, cancer https://novapharmanews.com/uploads/articles/pfizer-innovent-cancer-drug-alliance.webp Pfizer and Innovent Form $10.5 Billion Cancer Drug Alliance https://novapharmanews.com/eu/news/prac-meeting-highlights-may-2026 2026-05-30T16:27:02.421Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z PRAC Meeting Highlights: Regulatory Updates from May 2026 https://novapharmanews.com/uploads/articles/prac-meeting-highlights-may-2026.webp PRAC Meeting Highlights: Regulatory Updates from May 2026 https://novapharmanews.com/eu/news/italy-fourth-europe-clinical-research-enrollment 2026-05-30T16:27:00.736Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Italy Ranks Fourth in Europe for Clinical Research but Lags in Enrollment Speed https://novapharmanews.com/uploads/articles/italy-fourth-europe-clinical-research-enrollment.webp Italy Ranks Fourth in Europe for Clinical Research but Lags in Enrollment Speed https://novapharmanews.com/eu/news/2026-cell-therapy-regulatory-landscape 2026-05-30T16:27:57.689Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Navigating the 2026 Cell Therapy Regulatory Landscape cell therapy https://novapharmanews.com/uploads/articles/2026-cell-therapy-regulatory-landscape.webp Navigating the 2026 Cell Therapy Regulatory Landscape https://novapharmanews.com/eu/news/merz-therapeutics-kvvit-inbrija-agreement 2026-05-30T16:28:01.472Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® INBRIJA, levodopa https://novapharmanews.com/uploads/articles/merz-therapeutics-kvvit-inbrija-agreement.webp Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® https://novapharmanews.com/eu/news/pfizer-innovent-105bn-adc-oncology-partnership 2026-05-30T16:28:05.398Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Join Forces for $10.5bn ADC Oncology Partnership oncology https://novapharmanews.com/uploads/articles/pfizer-innovent-105bn-adc-oncology-partnership.webp Pfizer and Innovent Join Forces for $10.5bn ADC Oncology Partnership https://novapharmanews.com/eu/news/imfinzi-fda-approval-bladder-cancer 2026-05-30T16:28:06.929Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Imfinzi Receives FDA Approval for Bladder Cancer Treatment Imfinzi, oncology, bladder cancer https://novapharmanews.com/uploads/articles/imfinzi-fda-approval-bladder-cancer.webp Imfinzi Receives FDA Approval for Bladder Cancer Treatment https://novapharmanews.com/eu/news/critical-medicines-act-council-parliament-deal 2026-05-30T16:28:08.259Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Critical Medicines Act: Council and Parliament Reach Provisional Deal https://novapharmanews.com/uploads/articles/critical-medicines-act-council-parliament-deal.webp Critical Medicines Act: Council and Parliament Reach Provisional Deal https://novapharmanews.com/eu/news/pfizer-innovent-10-5bn-oncology-deal 2026-05-30T16:27:43.847Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Biologics' $10.5bn Oncology Deal: What It Means oncology, cancer https://novapharmanews.com/uploads/articles/pfizer-innovent-10-5bn-oncology-deal.webp Pfizer and Innovent Biologics' $10.5bn Oncology Deal: What It Means https://novapharmanews.com/eu/news/esmo-2025-preview-astra-daiichi-gilead 2026-05-30T16:28:14.577Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z ESMO 2025 Preview: Astra and Daiichi vs. Gilead oncology https://novapharmanews.com/uploads/articles/esmo-2025-preview-astra-daiichi-gilead.webp ESMO 2025 Preview: Astra and Daiichi vs. Gilead https://novapharmanews.com/eu/news/imfinzi-approval-bladder-cancer 2026-05-30T16:28:21.647Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer durvalumab, Imfinzi, oncology, non-muscle-invasive bladder cancer https://novapharmanews.com/uploads/articles/imfinzi-approval-bladder-cancer.webp IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer https://novapharmanews.com/apac/news/cell-gene-therapy-approvals-china-regulatory-updates 2026-05-30T16:26:12.065Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Cell and Gene Therapy Approvals in China: Latest Regulatory Updates gene therapy https://novapharmanews.com/uploads/articles/cell-gene-therapy-approvals-china-regulatory-updates.webp Cell and Gene Therapy Approvals in China: Latest Regulatory Updates https://novapharmanews.com/apac/news/regulatory-round-up-drug-approvals-april-20-2026 2026-05-30T16:26:48.320Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Regulatory Round-Up: Drug Approvals on April 20, 2026 https://novapharmanews.com/uploads/articles/regulatory-round-up-drug-approvals-april-20-2026.webp Regulatory Round-Up: Drug Approvals on April 20, 2026 https://novapharmanews.com/apac/news/premia-lind-ai-clinical-trial-screening-asia-pacific 2026-05-30T16:26:57.906Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z PREMIA and Lind Expand AI-Powered Clinical Trial Screening Across Asia-Pacific https://novapharmanews.com/uploads/articles/premia-lind-ai-clinical-trial-screening-asia-pacific.webp PREMIA and Lind Expand AI-Powered Clinical Trial Screening Across Asia-Pacific https://novapharmanews.com/apac/news/innovent-biologics-pfizer-10-5b-oncology-partnership 2026-05-30T16:26:25.744Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Innovent Biologics and Pfizer: A $10.5B Oncology Partnership oncology, cancer https://novapharmanews.com/uploads/articles/innovent-biologics-pfizer-10-5b-oncology-partnership.webp Innovent Biologics and Pfizer: A $10.5B Oncology Partnership https://novapharmanews.com/apac/news/onconic-therapeutics-jakubo-phase-3-clinical-trials-china 2026-05-30T16:26:19.122Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Onconic Therapeutics' Jakubo Enters Phase 3 Clinical Trials in China https://novapharmanews.com/uploads/articles/onconic-therapeutics-jakubo-phase-3-clinical-trials-china.webp Onconic Therapeutics' Jakubo Enters Phase 3 Clinical Trials in China https://novapharmanews.com/apac/news/clinical-trials-market-oncology-2034 2026-05-30T16:27:32.983Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Clinical Trials Market in Oncology: Size and Growth Insights for 2034 oncology https://novapharmanews.com/uploads/articles/clinical-trials-market-oncology-2034.webp Clinical Trials Market in Oncology: Size and Growth Insights for 2034 https://novapharmanews.com/us/news/fda-decisions-q2-2026-drug-approvals 2026-05-30T17:29:01.830Z NovaPharmaNews en-US 2026-05-29T04:28:06.695Z 5 FDA Decisions to Watch in Q2 2026: Drug Approvals https://novapharmanews.com/uploads/articles/fda-decisions-q2-2026-drug-approvals.webp 5 FDA Decisions to Watch in Q2 2026: Drug Approvals https://novapharmanews.com/apac/news/global-drug-discovery-market-2035 2026-05-30T11:23:57.027Z NovaPharmaNews en-AU 2026-05-29T04:28:00.259Z Global Drug Discovery Market to Exceed $174.92 Billion by 2035 https://novapharmanews.com/uploads/articles/global-drug-discovery-market-2035.webp Global Drug Discovery Market to Exceed $174.92 Billion by 2035 https://novapharmanews.com/us/news/longeveron-fda-meeting-elpis-ii-data 2026-05-30T11:22:43.042Z NovaPharmaNews en-US 2026-05-29T04:28:00.259Z Longeveron Secures Constructive FDA Meeting Ahead of ELPIS II Data Hypoplastic Left Heart Syndrome https://novapharmanews.com/uploads/articles/longeveron-fda-meeting-elpis-ii-data.webp Longeveron Secures Constructive FDA Meeting Ahead of ELPIS II Data https://novapharmanews.com/us/news/seven-biopharma-trends-2026-clinical-trials 2026-05-30T16:28:42.885Z NovaPharmaNews en-US 2026-05-29T04:28:00.259Z Seven Biopharma Trends to Watch in 2026: Clinical Trials Insights https://novapharmanews.com/uploads/articles/seven-biopharma-trends-2026-clinical-trials.webp Seven Biopharma Trends to Watch in 2026: Clinical Trials Insights https://novapharmanews.com/us/news/experimental-igg4-rd-drug-fda-submission 2026-05-30T15:22:55.905Z NovaPharmaNews en-US 2026-05-29T04:28:00.259Z Experimental IgG4-RD Drug Submission to FDA After Successful Trial IgG4-RD https://novapharmanews.com/uploads/articles/experimental-igg4-rd-drug-fda-submission.webp Experimental IgG4-RD Drug Submission to FDA After Successful Trial https://novapharmanews.com/us/news/fda-approves-durvalumab-bcg-high-risk-nmibc 2026-05-30T15:06:05.116Z NovaPharmaNews en-US 2026-05-29T04:28:00.259Z FDA Approves Durvalumab and BCG for High-Risk NMIBC Durvalumab, BCG, oncology, High-Risk NMIBC https://novapharmanews.com/uploads/articles/fda-approves-durvalumab-bcg-high-risk-nmibc.webp FDA Approves Durvalumab and BCG for High-Risk NMIBC https://novapharmanews.com/us/news/medicus-pharma-biotech-showcase-2026 2026-05-30T17:28:42.211Z NovaPharmaNews en-US 2026-05-29T04:28:00.259Z Medicus Pharma Ltd. to Present at Biotech Showcase 2026 https://novapharmanews.com/uploads/articles/medicus-pharma-biotech-showcase-2026.webp Medicus Pharma Ltd. to Present at Biotech Showcase 2026 https://novapharmanews.com/us/news/leap-therapeutics-stock-edges-higher 2026-05-30T08:43:00.503Z NovaPharmaNews en-US 2026-05-29T04:28:00.259Z Leap Therapeutics Stock Edges Higher After Recent Data https://novapharmanews.com/uploads/articles/leap-therapeutics-stock-edges-higher.webp Leap Therapeutics Stock Edges Higher After Recent Data https://novapharmanews.com/apac/news/sun-pharma-organon-acquisition-market-analysis 2026-05-30T11:23:07.804Z NovaPharmaNews en-AU 2026-05-29T04:28:00.259Z Sun Pharma's USD11.75bn Acquisition of Organon: Market Analysis https://novapharmanews.com/uploads/articles/sun-pharma-organon-acquisition-market-analysis.webp Sun Pharma's USD11.75bn Acquisition of Organon: Market Analysis https://novapharmanews.com/apac/news/middle-east-pharma-markets-api-china-2026 2026-05-30T16:57:20.319Z NovaPharmaNews en-AU 2026-05-29T04:28:00.259Z Middle East Pharma Markets: Strategic Growth at API China 2026 https://novapharmanews.com/uploads/articles/middle-east-pharma-markets-api-china-2026.webp Middle East Pharma Markets: Strategic Growth at API China 2026 https://novapharmanews.com/us/news/global-firms-china-deals-economic-uncertainty 2026-05-30T16:27:29.740Z NovaPharmaNews en-US 2026-05-29T04:27:54.063Z Global Firms Pursue China Deals Amid Economic Uncertainty https://novapharmanews.com/uploads/articles/global-firms-china-deals-economic-uncertainty.webp Global Firms Pursue China Deals Amid Economic Uncertainty https://novapharmanews.com/us/news/fda-draft-guidance-biosimilar-pk-studies 2026-05-30T16:27:48.991Z NovaPharmaNews en-US 2026-05-29T04:27:54.063Z FDA Draft Guidance Reduces Costs for Biosimilar PK Studies https://novapharmanews.com/uploads/articles/fda-draft-guidance-biosimilar-pk-studies.webp FDA Draft Guidance Reduces Costs for Biosimilar PK Studies https://novapharmanews.com/us/news/gsk-alfasigma-licensing-agreement-servier-acquisition 2026-05-30T16:27:59.161Z NovaPharmaNews en-US 2026-05-29T04:27:54.063Z GSK and Alfasigma Licensing Agreement, Servier's $2.5B Acquisition Linerixibat https://novapharmanews.com/uploads/articles/gsk-alfasigma-licensing-agreement-servier-acquisition.webp GSK and Alfasigma Licensing Agreement, Servier's $2.5B Acquisition https://novapharmanews.com/us/news/us-fda-decision-date-camizestrant-extended 2026-05-30T15:07:18.371Z NovaPharmaNews en-US 2026-05-29T04:27:54.063Z US FDA Extends Decision Date for Camizestrant Filing camizestrant, oncology https://novapharmanews.com/uploads/articles/us-fda-decision-date-camizestrant-extended.webp US FDA Extends Decision Date for Camizestrant Filing https://novapharmanews.com/us/news/fda-loosens-regulations-digital-health-tools 2026-05-30T05:00:46.012Z NovaPharmaNews en-US 2026-05-29T04:27:54.063Z FDA Loosens Regulations on Digital Health Tools https://novapharmanews.com/uploads/articles/fda-loosens-regulations-digital-health-tools.webp FDA Loosens Regulations on Digital Health Tools https://novapharmanews.com/us/news/biopharma-dealmaking-2025-market-analysis 2026-05-30T16:28:00.581Z NovaPharmaNews en-US 2026-05-29T04:27:54.063Z Biopharma Dealmaking in 2025: Market Analysis https://novapharmanews.com/uploads/articles/biopharma-dealmaking-2025-market-analysis.webp Biopharma Dealmaking in 2025: Market Analysis https://novapharmanews.com/eu/news/liquid-biopsy-breast-cancer-improvements 2026-05-30T16:27:45.963Z NovaPharmaNews en-GB 2026-05-29T04:27:54.063Z Liquid Biopsy: Transforming Breast Cancer Treatment oncology, breast cancer https://novapharmanews.com/uploads/articles/liquid-biopsy-breast-cancer-improvements.webp Liquid Biopsy: Transforming Breast Cancer Treatment https://novapharmanews.com/apac/news/apac-clinical-trial-growth-oncology 2026-05-30T15:11:25.046Z NovaPharmaNews en-AU 2026-05-29T04:27:54.063Z Medical Advances Soar With APAC's Clinical Trial Growth in Oncology oncology https://novapharmanews.com/uploads/articles/apac-clinical-trial-growth-oncology.webp Medical Advances Soar With APAC's Clinical Trial Growth in Oncology https://novapharmanews.com/apac/news/big-pharma-china-trials-scrutiny-oncology 2026-05-30T12:01:34.066Z NovaPharmaNews en-AU 2026-05-29T04:27:54.063Z Big Pharma’s China Trials: A Scrutiny Escape in Oncology oncology https://novapharmanews.com/uploads/articles/big-pharma-china-trials-scrutiny-oncology.webp Big Pharma’s China Trials: A Scrutiny Escape in Oncology https://novapharmanews.com/apac/news/exosome-based-therapeutics-market-2033-report 2026-05-30T14:14:01.314Z NovaPharmaNews en-AU 2026-05-29T04:27:54.063Z Exosome-based Therapeutics Market Insights: 2033 Industry Report https://novapharmanews.com/uploads/articles/exosome-based-therapeutics-market-2033-report.webp Exosome-based Therapeutics Market Insights: 2033 Industry Report https://novapharmanews.com/apac/news/hong-kong-new-drug-approval-process 2026-05-30T11:57:30.242Z NovaPharmaNews en-AU 2026-05-29T04:27:54.063Z Hong Kong's New Drug Approval Process: Key Changes Ahead https://novapharmanews.com/uploads/articles/hong-kong-new-drug-approval-process.webp Hong Kong's New Drug Approval Process: Key Changes Ahead https://novapharmanews.com/apac/news/regulatory-strategy-reimagined-trends-accelerating-drug-development 2026-05-30T07:02:54.516Z NovaPharmaNews en-AU 2026-05-29T04:27:54.063Z Regulatory Strategy Reimagined: Trends Accelerating Drug Development https://novapharmanews.com/uploads/articles/regulatory-strategy-reimagined-trends-accelerating-drug-development.webp Regulatory Strategy Reimagined: Trends Accelerating Drug Development https://novapharmanews.com/apac/news/ai-tools-clinical-trials-life-sciences 2026-05-30T15:05:00.560Z NovaPharmaNews en-AU 2026-05-29T04:27:54.063Z AI Tools Transforming Clinical Trials in Life Sciences https://novapharmanews.com/uploads/articles/ai-tools-clinical-trials-life-sciences.webp AI Tools Transforming Clinical Trials in Life Sciences https://novapharmanews.com/eu/news/ema-management-board-march-2026-clinical-trials 2026-05-30T16:27:48.469Z NovaPharmaNews en-GB 2026-05-29T04:27:54.063Z EMA Management Board Meeting Highlights: March 2026 on Clinical Trials https://novapharmanews.com/uploads/articles/ema-management-board-march-2026-clinical-trials.webp EMA Management Board Meeting Highlights: March 2026 on Clinical Trials https://novapharmanews.com/eu/news/critical-medicines-act-europe-medicines-shortages 2026-05-30T16:27:27.618Z NovaPharmaNews en-GB 2026-05-29T04:27:54.063Z Critical Medicines Act Targets Europe's Medicines Shortages https://novapharmanews.com/uploads/articles/critical-medicines-act-europe-medicines-shortages.webp Critical Medicines Act Targets Europe's Medicines Shortages https://novapharmanews.com/eu/news/imfinzi-approved-bladder-cancer-combo 2026-05-30T16:27:45.539Z NovaPharmaNews en-GB 2026-05-29T04:27:54.063Z Imfinzi Approved for Unique Bladder Cancer Combo: A Game Changer Imfinzi, oncology, bladder cancer https://novapharmanews.com/uploads/articles/imfinzi-approved-bladder-cancer-combo.webp Imfinzi Approved for Unique Bladder Cancer Combo: A Game Changer https://novapharmanews.com/eu/news/tarsier-pharma-ipo-nyse-listings-expand 2026-05-30T16:27:47.263Z NovaPharmaNews en-GB 2026-05-29T04:27:54.063Z Tarsier Pharma IPO: NYSE Listings Expand with New Opportunities https://novapharmanews.com/uploads/articles/tarsier-pharma-ipo-nyse-listings-expand.webp Tarsier Pharma IPO: NYSE Listings Expand with New Opportunities https://novapharmanews.com/eu/news/definitive-trial-milestone-50-percent-recruitment 2026-05-30T13:30:53.772Z NovaPharmaNews en-GB 2026-05-29T04:27:54.063Z DEFINITIVE Trial Milestone: 50% Recruitment Achieved oncology https://novapharmanews.com/uploads/articles/definitive-trial-milestone-50-percent-recruitment.webp DEFINITIVE Trial Milestone: 50% Recruitment Achieved https://novapharmanews.com/eu/news/hansa-licenses-idefirix-serb-133m 2026-05-30T17:12:50.299Z NovaPharmaNews en-GB 2026-05-29T04:27:54.063Z Hansa Licenses Idefirix to SERB for $133M: Implications for Investors Idefirix https://novapharmanews.com/uploads/articles/hansa-licenses-idefirix-serb-133m.webp Hansa Licenses Idefirix to SERB for $133M: Implications for Investors https://novapharmanews.com/eu/news/camizestrant-eu-approval-advanced-er-positive-breast-cancer 2026-05-30T16:28:27.637Z NovaPharmaNews en-GB 2026-05-29T04:27:54.063Z Camizestrant Recommended for Approval in the EU for Advanced ER-Positive Breast Cancer camizestrant, breast cancer, advanced ER-positive breast cancer https://novapharmanews.com/uploads/articles/camizestrant-eu-approval-advanced-er-positive-breast-cancer.webp Camizestrant Recommended for Approval in the EU for Advanced ER-Positive Breast Cancer